




# Scaling Social Alpha: The Long-Acting HIV Breakthrough

Dr. Leonildo Delgado, PhD in Struct. Biology and Biophysics,  
Portfolio Manager of the JSS Sustainable Equity – Future Health Fund

While environmental targets have long dominated the ESG spotlight, the “Social” pillar is taking center stage through innovations in global health equity. HIV remains a critical threat, with 39.9 million people living with the virus - 65% in Africa. However, a significant shift is underway. Gilead Sciences’ Yeztugo, a first-in-class, twice-yearly PrEP (pre-exposure prophylaxis) injection approved in 2025, is “bending the curve” of the epidemic. Boasting over 99.9% efficacy, this breakthrough innovation dismantles traditional barriers such as daily pill fatigue and social stigma. This is only the beginning; the pipeline is already advancing toward the next milestone: a once-yearly HIV “vaccine”. Strategically, Gilead’s commitment to enable access to Yeztugo at no profit to various high-burden, low-income countries, marks a transition toward targeted impact. By replacing years of “access lag” with proactive scalability, this model redefines how the healthcare sector creates and sustains value.

## HIV Incidence Rates by Region (2024)

Source: [https://www.who.int/data/gho/data/indicators/indicator-details/GHO/new-hiv-infections-\(per-1000-uninfected-population\)](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/new-hiv-infections-(per-1000-uninfected-population))



Important Information: This publication is not an offer to buy or sell any financial instrument and does not constitute investment advice.



Scan to see more